Screener
Viking Therapeutics VKTX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization of investment premiums | (1,293) | (3,133) |
| Amortization of financing costs | — | 24 |
| Stock-based compensation | 10,337 | 11,348 |
| Amortization of right-of-use assets | 85 | 111 |
| Interest expense related to operating lease liability | 1 | 10 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 4,628 | (9,554) |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's stock-based comp?
- Viking Therapeutics (VKTX) reported stock-based comp of $10.34M in Q1 2026.
- How has Viking Therapeutics's stock-based comp changed year-over-year?
- Viking Therapeutics's stock-based comp decreased by 8.9% year-over-year, from $11.35M to $10.34M.
- What is the long-term trend for Viking Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Viking Therapeutics's stock-based comp has grown at a 60.8% compound annual growth rate (CAGR), from $6.1M to $40.82M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Viking Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude